Portal de Periódicos da CAPES

Discovery of ( S )-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

2014; American Chemical Society; Volume: 57; Issue: 18 Linguagem: Inglês

10.1021/jm500510f

1520-4804

Hong Jia, Guangxiu Dai, Jianyang Weng, Zhulin Zhang, Qing Wang, Feng Zhou, Longxian Jiao, Yumin Cui, Yongxin Ren, Shiming Fan, Jinghong Zhou, Weiguo Qing, Yi Gu, Jian Wang, Yang Sai, Weiguo Su,

Digestive system and related health

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure–activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.